Trial · NCT04447469
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 | Day 29 | Phase 2: Modified Intent-to-Treat (mITT) Analysis Set: All randomized participants who passed screening and received study drug (two enrolled and treated participants \[1 each in the 6 mg/kg and placebo groups\] were randomized and dosed in violation of inclusion/exclusion criteria and were thus excluded from this Set). | percentage of participants | NUMBER |
| PRIMARY | Cohort 1, Phase 3: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 | Day 29 | Phase 3: Intent-to-Treat (ITT) Analysis Set: All randomized participants. | percentage of participants | NUMBER |
| PRIMARY | Cohort 2, Phase 2: Percentage of Participants Who Died by Day 29 | Day 29 | Phase 2: Modified Intent-to-Treat (mITT) Analysis Set: All randomized participants who passed screening and received study drug (two enrolled and treated participants \[1 each in the 6 mg/kg and placebo groups\] were randomized and dosed in violation of inclusion/exclusion criteria and were thus excluded from this Set). | percentage of participants | NUMBER |
| PRIMARY | Cohort 2, Phase 3: Percentage of Participants Who Died by Day 29 | Day 29 | Phase 3: Intent-to-Treat (ITT) Analysis Set: All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Cohort 1, Phase 2: Time to 2-point Clinical Improvement by Day 29 | Day 29 | Phase 2: Modified Intent-to-Treat (mITT) Analysis Set: All randomized participants who passed screening and received study drug (two enrolled and treated participants \[1 each in the 6 mg/kg and placebo groups\] were randomized and dosed in violation of inclusion/exclusion criteria and were thus excluded from this Set). | days | MEDIAN |
| SECONDARY | Phase 2, Cohort 1: Time to Return to Room Air or Discharge by Day 29 | Day 29 | Phase 2: Modified Intent-to-Treat (mITT) Analysis Set: All randomized participants who passed screening and received study drug (two enrolled and treated participants \[1 each in the 6 mg/kg and placebo groups\] were randomized and dosed in violation of inclusion/exclusion criteria and were thus excluded from this Set). | days | MEDIAN |
| SECONDARY | Phase 2, Cohort 1: Percentage of Participants Who Die by Day 29 | Day 29 | Phase 2: Modified Intent-to-Treat (mITT) Analysis Set: All randomized participants who passed screening and received study drug (two enrolled and treated participants \[1 each in the 6 mg/kg and placebo groups\] were randomized and dosed in violation of inclusion/exclusion criteria and were thus excluded from this Set). | percentage of participants | NUMBER |
| SECONDARY | Phase 2, Cohort 2: Time to 1-Point Clinical Improvement by Day 29 | Day 29 | Phase 2: Modified Intent-to-Treat (mITT) Analysis Set: All randomized participants who passed screening and received study drug. | days | MEDIAN |
| SECONDARY | Phase 3, Cohort 1: Percentage of Participants Who Died at Day 29 | Day 29 | Phase 3: Intent-to-Treat (ITT) Analysis Set: All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Phase 3, Cohort 1: Ventilation-Free Survival (Time to Ventilation or Death) by Day 29 | Day 29 | Phase 3: Intent-to-Treat (ITT) Analysis Set: All randomized participants. | days | MEDIAN |
| SECONDARY | Phase 3, Cohort 1: Overall Survival by Day 29 | Day 29 | Phase 3: Intent-to-Treat (ITT) Analysis Set: All randomized participants. | days | MEDIAN |
| SECONDARY | Phase 3, Cohort 2: Time to 1-point Clinical Improvement by Day 29 | Day 29 | Phase 3: Intent-to-Treat (ITT) Analysis Set: All randomized participants. | days | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04447469/outcomes